And P2X7 receptors in neurodegeneration. Eur J Pharmacol 2002; 447: 26169. 35. Skaper SD, Debetto P, Giusti P. The P2X7 purinergic receptor: from physiology to neurological problems. FASEB J 2010; 24: 33745. 36. Franke H, Gunther A, Grosche J, Schmidt R, Rossner S, Reinhardt R et al. P2X7 receptor expression right after ischemia inside the cerebral cortex of rats. J Neuropathol Exp Neurol 2004; 63: 68699. 37. Narcisse L, Scemes E, Zhao Y, Lee SC, Brosnan CF. The cytokine IL-1beta transiently enhances P2X7 receptor expression and function in human astrocytes. Glia 2005; 49: 24558. 38. John GR, Simpson JE, Woodroofe MN, Lee SC, Brosnan CF. Extracellular nucleotides differentially regulate interleukin-1beta signaling in major human astrocytes: implications for inflammatory gene expression. J Neurosci 2001; 21: 4134142. 39. Panenka W, Jijon H, Herx LM, Armstrong JN, Feighan D, Wei T et al. P2X7-like receptor activation in astrocytes increases chemokine monocyte chemoattractant protein-1 expression via mitogen-activated protein kinase. J Neurosci 2001; 21: 7135142. 40. Peng W, Cotrina ML, Han X, Yu H, Bekar L, Blum L et al. Systemic administration of an antagonist of your ATP-sensitive receptor P2X7 improves recovery soon after spinal cord injury. Proc Natl Acad Sci USA 2009; 106: 124892493. 41. Brockes JP, Fields KL, Raff MC. Studies on cultured rat Schwann cells. I. Establishment of purified populations from cultures of peripheral nerve. Brain Res 1979; 165: 10518. 42. Luo J, Bo X, Wu D, Yeh J, Richardson PM, Zhang Y. Promoting survival, migration, and integration of transplanted Schwann cells by over-expressing polysialic acid. Glia 2011; 59: 42434. 43. Zhang Y, Zhang X, Yeh J, Richardson P, Bo X. Engineered expression of polysialic acid enhances Purkinje cell axonal regeneration in L1/GAP-43 double transgenic mice. Eur J Neurosci 2007; 25: 35161. 44. Chessell IP, Hatcher JP, Bountra C, Michel AD, Hughes JP, Green P et al. Disruption with the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain 2005; 114: 38696.Cell Death and Disease is an open-access journal published by Nature Publishing Group. This operate is licensed under a Inventive Commons Attribution-NonCommercialShareAlike three.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/Cell Death and Disease
Havre et al. BMC Cancer 2013, 13:517 http://www.Amprenavir biomedcentral/1471-2407/13/RESEARCH ARTICLEOpen AccessCD26 Expression on T-Anaplastic Massive Cell Lymphoma (ALCL) Line Karpas 299 is linked with improved expression of Versican and MT1-MMP and enhanced adhesionPamela A Havre1, Extended H Dang1, Kei Ohnuma2, Satoshi Iwata2, Chikao Morimoto2 and Nam H Dang1,3*AbstractBackground: CD26/dipeptidyl peptidase IV (DPPIV) can be a multifunctional membrane protein using a key function in T-cell biology and also serves as a marker of aggressive cancers, which includes T-cell malignancies.Tisotumab vedotin Procedures: Versican expression was measured by real-time RT-PCR and Western blots.PMID:24513027 Gene silencing of versican in parental Karpas 299 cells was performed employing transduction-ready viral particles. The effect of versican depletion on surface expression of MT1-MMP was monitored by flow cytometry and surface biotinylation. CD44 secretion/ cleavage and ERK (1/2) activation was followed by Western blotting. Collagenase I activity was measured by a live cell assay and in vesicles utilizing a liquid-phase assay. Adhesion to collagen I was quantified by an MTS assay. Results: Versic.
